Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis

著者: Solange Peters, S.S. Ramalingam, Luis Paz‐Ares, R. Bernabe Caro, Bogdan Żurawski, S.-W. Kim, Aurelia Alexandru, Lorena Lupinacci, Emmanuel de la Mora Jimenez, Hiroshi Sakai, István Albert, A. Vergnenègre, Martin Reck, Hossein Borghaei, Julie R. Brahmer, Kenneth J. O’Byrne, William J. Geese, Prabhu Bhagavatheeswaran, Faith E. Nathan, Matthew D. Hellmann - Annals of Oncology 2019 被引用: 33